STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Q3 2023 Earnings Presentation
12 slides from STRATA Skin Sciences's earnings presentation, Nov 15, 2023
Slide 1: 3Q 2023 Earnings Conference Call and Webcast
NASDAQ: SSKN 3Q 2023 Earnings Conference Call and Webcast | November 14, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,”
Slide 3: Third Quarter 2023 Highlights
Third Quarter 2023 Highlights Comparative 3Q Revenues (Dollars in thousands) Three Months Ended Nine Months Ended 3Q 2022 3Q 2023 $0 $2,000 $4,000 $6,000 $8,000 $10,000 Dr. Dolev Rafaeli was named the new Vice-Chairman, President and CEO Placed 81 TheraClear®X devices as of September 30, 2023 Non-GA
Slide 4: Total Revenue and Balance Sheet
Total Revenue (Dollars in thousands) Balance Sheet $8.5M cash & cash equivalents* Increased YoY from additional proceeds from refinancing Senior Term Facility on June 30, 2023 Annualized Financials 2020 2021 2022 2023* $0 $10,000 $20,000 $30,000 $40,000 $23,090 *As of September 30, 2023. 4 $29,977 $
Slide 5: Revenue Mix: Domestic and International
Domestic International 3Q 2022 3Q 2023 $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 3Q 2022 3Q 2023 $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 Revenue Mix *As of September 30, 2023. 5 $6,099 $3,314 $5,839 $3,013 $5,280 $3,566 $5,847 $3,572
Slide 6: Non-GAAP Adjusted EBITDA
3Q 2022 4Q 2022 1Q 2023 2Q 2023 3Q 2023 $-1,000 $-500 $0 $500 $1,000 $1,500 Three Months Ended Comparison (In thousands) Improved 21% YoY 6 Non-GAAP Adjusted EBITDA Continued improvement to net loss over periods from G&A, S&M reduction
Slide 7: A True Partnership Delivering a Complete Business Solution
DTC Marketing Clinical Support Customer Support Reimbursement Support* Co-pay Assistance Field Service Support Consumables and Parts Laser Upgrades* A True Partnership Delivering a Complete Business Solution *Reimbursement Support and Laser Upgrades only applies to XTRAC® 7
Slide 8: Domestic XTRAC Revenue Funnel
IN-HOUSE CALL CENTER 8 VERIFY XTRAC TREATMENT REOCCURRENCE ASSIGNING A DOCTOR PARTNER PATIENT APPOINTMENT TREATMENT INSURANCE ADVOCACY WIN-WIN-WIN DOCTOR+PATIENT+PAYER Domestic XTRAC Revenue Funnel DTC ADVERTISING VERIFY APPOINTMENT INTEREST CREATION DTC expands Patient Leads Patient Leads turn into
Slide 9: Patient Leads Drive Recurring Sales
Leads Appointments RDX Charts (New Patient Charts) 2018 2019 2020 2021 2022 2023* 0 10,000 20,000 30,000 40,000 50,000 * Thru October 2023 Patient Leads Drive Recurring Sales 21,939 4,011 18,733 47,429 6,203 22,711 19,223 2,729 15,555 33,164 4,896 21,332 19,698 2,830 15,965 177 38 9,973 Recurring Re
Slide 10: Domestic Strategy: Core Business Refocused to Recurring Revenue
Average Recuring Revenue/Device Domestic Strategy Core Business Refocused to Recurring Revenue US Installed Base 746 820 832 898 909 929 $7,055 $7,209 $5,062 $5,906 $5,923 $5,235 2022 2023* *As of October 31, 2023. 2018 2019 2020 2021 2022 2023* 2018 2019 2020 2021 US Recurring Revenue Growth Achiev
Slide 11: Closing Remarks
Closing Remarks Reallocating advertising spending to prioritize DTC Redirecting TheraClearX from the aesthetics market to the medical market Reigniting the customer experience and value to our clinical partners 11
Slide 12: Q&A Session
Shs Client Ee Q&A Session STRATA